Sable Therapeutics Enter into Agreement with Columbia University to Develop Novel Polycation Nanomedicines
Monday, August 12, 2024
Sable Therapeutics has announced an exclusive global licensing agreement with Columbia University.
This collaboration aims to advance a new range of polycation nanomedicines, SBL-001 and SBL-002, designed to treat visceral and subcutaneous fat. Through this agreement, Sable Therapeutics gains exclusive rights to develop and commercialise intellectual property.
SBL-001 and SBL-002 are innovative compounds specifically designed to target fat cells and reduce their volume by up to 70%. These compounds also have the potential to serve as a delivery system for other fat-reducing agents, such as GLP-1s.
This research from the lab to clinical development, highlighting its potential as a powerful tool in the fight against obesity. This agreement distinguishes the company in the aesthetic and obesity-related markets and emphasised the value of their partnership with Columbia University in developing new treatments for fat reduction.
Source:prnewswire.com
